Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C

Journal of Hepatology

Volumn 37, Issue 6, 2002, Pages 848-854

  Bonkovsky, Herbert L ^a,b   Troy, Nicole ^a   McNeal, Kristina ^a   Banner, Barbara F ^a   Sharma, Ashish ^a   Obando, Jorge ^a   Mehta, Savant ^a   Koff, Raymond S ^a   Liu, Qin ^a   Hsieh, Chung Cheng ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Body mass index; C282Y; Chronic hepatitis C; Comorbidity; H63D genetic polymorphisms; Hemochromatosis; Hepatic cirrhosis; Hepatic fibrosis; Hepatic iron; HFE; Interferon; Ribavirin; TfR1

Indexed keywords

CD71 ANTIGEN; CYSTEINE; HFE PROTEIN; IRON; TRANSFERRIN RECEPTOR; TYROSINE; UNCLASSIFIED DRUG; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; MEMBRANE PROTEIN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CHRONIC HEPATITIS; COMORBIDITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; SCORING SYSTEM; GENETICS; GENOTYPE; HETEROZYGOTE; LIVER; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; VIROLOGY;

ADULT; DISEASE PROGRESSION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HETEROZYGOTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON; LIVER; LIVER CIRRHOSIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; RECEPTORS, TRANSFERRIN;

EID: 0036893631     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00305-7     Document Type: Article

References (34)

1. Brissot P. Clinical spectrum of hepatic disease in hemochromatosis. In: Barton JC, Edwards CQ, editors. Hemochromatosis - Genetics, Pathophysiology, Diagnosis and Treatment, Cambridge, UK: Cambridge University Press, 2000. pp. 250-257.
2. Powell LW, Leggett BA, Crawford DHG. Hemochromatosis and other iron storage disorders. In: Schiff ER, Sorrell MF, Maddrey WC, editors. Diseases of the Liver, 8th Ed. Philadelphia, PA: Lippincott, Williams and Wilkins, 1999. pp. 1107-1130.
3. Elevado M, Bonkovsky HL. Hemochromatosis. In: Rakel RE, Bope ET, editors. Conn's Current Therapy, 55th Ed. Philadelphia, PA: Saunders, 2002 in press.
4. Bonkovsky HL, Banner BF, Lambrecht RW, Rubin RB. Iron in liver diseases other than hemochromatosis. Semin Liver Dis 1996;16:65-82.
5. Bonkovsky HL, Obando JV. Role of HFE gene mutations in liver diseases other than hereditary hemochromatosis. Curr Gastroenterol Rep 1999;1:30-37.
6. Sampietro M, Piperno A, Lupica L, Arioso C, Vergani A, Corbetta N, et al. High prevalence of the His 63 Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology 1998;27:181-184.
7. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, Obando J, DiBisceglie A, Tattrie C, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998;27:1661-1669.
8. Bonkovsky HL, Jawaid O, Tortorelli K, LeClair P, Cobb J, Lambrecht RW, Banner BF. Non-alcoholic steatohepatitis and iron: Increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999;31:421-429.
9. Bonkovsky HL, Zivny J, Tortorelli K, Liu Q, Lambrecht RW. Non-alcoholic steatohepatitis with iron: Part of insulin resistance-associated hepatic iron overload?. J Hepatol 2000;33:1025-1026.
10. Beckman LE, VanLandeghem GF, Sikström C. Wahlin A, Markevärn B, Hollmans G, et al. Interaction between hemochromatosis and transferrin receptor genes in different neoplastic disorders. Carcinogenesis 1999;20:1231-1233.
11. Vanlandeghem GF, Beckman LE, Wahlin A, Markevärn B, Beckman L. Interaction between hemochromatosis and transferrin receptor genes in multiple myeloma. Lancet 1998;352:1285-1286.
12. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997;25:759-768.
13. Smith BC, Grove J, Guzail MA, Day CP, Daly AK, Burt AD, Bassendine MF. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998;27:1695-1699.
14. Kazemi-Shirazi L, Datz C, Maier-Dobersberger T, Kaserer K, Hackl F, Polli C, et al. The relationship of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology 1999;116:127-134.
15. Bonkovsky HL, McNeal KT, Sharma S, Banner B, Liu Q, Obando J, Hsieh C-C. Iron and HFE mutations as comorbid factors for development and progression of chronic hepatitis C [abstract]. Hepatology 2001;34:224A.
16. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative study group. Hepatology 1996;24:289-293.
17. MacSween RNM, Anthony PP, Scheuer PJ. Pathology of the Liver, Edinburgh: Churchill Livingstone. 1987. p. 185.
18. Steinberg KK, Cogswell ME, Chang JC, Candill SP, McQuillan GM, Bowman BA, et al. Prevalence of C282Y and H63D mutations in the hemochromatosis HFE gene in the United States. J Am Med Assoc 2001;285:2216-2222.
19. Martinelli ALC, Franco RF, Villanova MG, Figueiredo JFC, Secaf M, Tavella MH, et al. Are haemochromatosis mutations related to the severity of liver disease in hepatitis C viras infection? Acta Haematol 1999;102:152-156.
20. Negro F, Samii K, Rubia-Brandt L, Quadri R, Male P-J, Zarski J-P. et al. Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis. J Med Virol 2000;60:21-27.
21. Diwakaran HH, Befeler AS, Britton RS, Brunt EM, Bacon BR. Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J Hepatol 2002;36:687-691.
22. Avellini M, Prisi M, Scott P, Toniatto C, Fabris G, Soardo D, et al. Association of HFE missense mutations with advanced staging in chronic hepatitis C [abstract]. Digestion 1998;59(Suppl 3):517.
23. DeSousa M, Porto G. The immunological system in hemochromatosis. J Hepatol 1998;28(1):Suppl 1-7.
24. Lustbader ED, Hann HL, Blumberg BS. Serum ferritin as a predictor of host response to hepatitis B virus infection. Science 1983;220:423-425.
25. Bonkovsky HL, Lambrecht RW. Iron-induced liver injury. Clin Liver Dis 2000;4:409-429.
26. Jain SK, Pemberton PW, Smith A, McMahon RFT, Burrows PC, Aboutwerat A, Warnes TW. Oxidative stress in chronic hepatitis C: Not just a feature of late stage disease. J Hepatol 2002;36:805-811.
27. Fong TL, Han SH, Tsai NCS, Morgan TR, Mizokami M, Qian DJ, et al. A pilot randomized, controlled trial of the effect of iron depletion on long term response to alpha-interferon in patients with chronic hepatitis C. J Hepatol 1998;28:369-374.
28. Fontana RJ, Israel J, LeClair P, Banner BF, Tortorelli K, Grace N, et al. Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial. Hepatology 2000;31:730-736.
29. Fargion S, Ballane M, Belloni G, Bissoli F, Borzio M, Cerrini R, et al. Iron depletion and interferon therapy: A multicenter randomized controlled trial in untreated non-cirrhotic patients with chronic hepatitis C [abstract]. Hepatology 1999;30:371A.
30. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peg interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358:958-965.
31. Bonkovsky HL, Stefancyk D, Tortorelli K, Banner BF, Liu Q, Zucker G, et al. Comparative effects of different doses of ribavirin plus interferon alpha-2b for therapy of chronic hepatitis C: Results of a controlled, randomized trial. Dig Dis Sci 2001;46:2051-2059.
32. Fried MM, Shiffman ML, Reddy RK, Smith C, Marino G, Goncales Jr F, et al. Pegylated (40kDa) interferon-alfa 2a (PEGASYS) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study [abstract]. Gastroenterology 2001;120(Suppl 1):A55.
33. Yano M, Hayashi H, Wakusawa S, Sanae F, Takikawa T, Shiono Y, et al. Long-term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. Am J Gastroenterol 2002;97:133-137.
34. Bonkovsky HL. Iron as a comorbid factor in chronic viral hepatitis. Am J Gastroenterol 2002;97:1-4.